Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.

Grace Lai-Hung WongY-K TseT C-F YipH L-Y ChanK K-F TsoiVincent Wai-Sun Wong

Published in: Alimentary pharmacology & therapeutics (2017)

Oral nucleos(t)ide analogue treatment does not appear to increase cancer risk in patients with chronic hepatitis B. Given the beneficial effect on liver outcomes, our data support the current practice of long-term anti-viral therapy.

Keyphrases

hepatitis b virus
primary care
healthcare
stem cells
molecular docking
type diabetes
combination therapy
metabolic syndrome
replacement therapy
deep learning
artificial intelligence
weight loss